Edition:
United States

Veru Inc (VERU.OQ)

VERU.OQ on NASDAQ Stock Exchange Capital Market

1.79USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$1.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
25,991
52-wk High
$2.99
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

U.S. FDA Grants Fee Waiver For Tamsulosin Drs New Drug Application
Thursday, 22 Mar 2018 08:30am EDT 

March 22 (Reuters) - Veru Inc ::FDA GRANTS FEE WAIVER FOR TAMSULOSIN DRS NEW DRUG APPLICATION.VERU - U.S. FDA GRANTED APPLICATION FOR SMALL BUSINESS WAIVER OF DRUG APPLICATION FEE OF ABOUT$2.4 MILLION FOR NDA FOR TAMSULOSIN DELAYED RELEASE SACHET.  Full Article

Veru Says On March 5 Entered Into Credit Agreement For Synthetic Royalty Financing Transaction
Tuesday, 6 Mar 2018 01:00pm EST 

March 6 (Reuters) - Veru Inc ::VERU SAYS ON MARCH 5, ENTERED INTO CREDIT AGREEMENT FOR SYNTHETIC ROYALTY FINANCING TRANSACTION - SEC FILING.VERU - PER TERMS OF CREDIT AGREEMENT, LENDERS TO PROVIDE CO WITH MULTI-DRAW TERM LOAN OF UP TO $12 MILLION.VERU INC - IN CONNECTION WITH CREDIT AGREEMENT, VERU AND SWK FUNDING ALSO ENTERED INTO A RESIDUAL ROYALTY AGREEMENT, DATED AS OF MARCH 5, 2018.VERU INC - CO RECEIVED NET PROCEEDS OF ABOUT $9.9 MILLION FROM INITIAL $10 MILLION ADVANCE UNDER CREDIT AGREEMENT.  Full Article

Veru Q1 Loss Per Share $0.08
Wednesday, 14 Feb 2018 06:30am EST 

Feb 14 (Reuters) - Veru Inc ::VERU REPORTS FISCAL 2018 FIRST-QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.08.Q1 REVENUE $2.6 MILLION VERSUS $3.2 MILLION.REMAIN ON TRACK TO FILE WITH FDA COMPANY'S FIRST NDA FOR TAMSULOSIN DRS IN 2018.PLAN TO SUBMIT TWO ADDITIONAL NDAS IN 2019.  Full Article

Veru Inc - On Jan 4, 2018, Daniel Haines, CFO, Informed Co That He Was Resigning ‍​
Wednesday, 10 Jan 2018 05:08pm EST 

Jan 10 (Reuters) - Veru Inc ::VERU INC - ON JAN 4, 2018, DANIEL HAINES, CFO, INFORMED CO THAT HE WAS RESIGNING ‍​.VERU SAYS ‍HAINES' DUTIES AS CFO WERE ASSIGNED EFFECTIVE JAN 4, 2018 TO MICHELE GRECO​ - SEC FILING.  Full Article

Veru reports Q4 Loss Per Share $0.10
Tuesday, 2 Jan 2018 07:00am EST 

Jan 2 (Reuters) - Veru Inc ::VERU REPORTS FISCAL 2017 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE $3.7 MILLION VERSUS $3.6 MILLION.  Full Article

Veru Acquires Novel Proprietary Formulation For Overactive Bladder
Monday, 11 Dec 2017 08:30am EST 

Dec 11 (Reuters) - Veru Inc ::VERU ACQUIRES NOVEL PROPRIETARY FORMULATION FOR OVERACTIVE BLADDER.VERU PLANS TO BEGIN SOLIFENACIN DRG BIOEQUIVALENCE STUDY IN 2018 AND TO FILE NDA IN 2019.‍UNDER TERMS OF AGREEMENT WITH CAMARGO, VERU PAID AN UNDISCLOSED UPFRONT FEE TO ACQUIRE ASSET​.UNDER TERMS, VERU TO PAY UNDISCLOSED MILESTONE FEES UPON SUCCESSFUL CLINICAL DEVELOPMENT, LOW SINGLE DIGIT ROYALTY UPON COMMERCIAL SALES​.FDA ‍CONFIRMED IN A MEETING WITH CO THAT REGULATORY APPROVAL FOR SOLIFENACIN DRG WILL REQUIRE A SINGLE BIOEQUIVALENCE STUDY​.  Full Article

Veru announces Tamsulosin drs bioequivalence clinical trial results
Monday, 13 Nov 2017 08:30am EST 

Nov 13 (Reuters) - Veru Inc :Veru announces Tamsulosin Drs bioequivalence clinical trial results.Veru Inc - ‍Expected timing of additional formulation adjustment should allow us to remain on track for a pre-NDA meeting in early 2018​.  Full Article

Veru files for mixed shelf of up to $50 million
Wednesday, 25 Oct 2017 05:49pm EDT 

Oct 25 (Reuters) - Veru Inc :Files for mixed shelf of up to $50 million - SEC filing‍​.  Full Article

Veru announces agreement with Timm Medical Technologies to distribute and to promote preboost
Tuesday, 3 Oct 2017 08:30am EDT 

Oct 3 (Reuters) - Veru Inc :Veru Inc announces agreement with Timm Medical Technologies LLC to distribute and to promote preboost.Veru Inc - signed United States distribution and co-promotion agreement with Timm Medical Technologies for preboost for prevention of premature ejaculation.Veru Inc - Veru grants Timm Medical Technologies distribution and promotion rights of preboost in United States and its territories.Veru Inc - Veru retains rights to also distribute and promote preboost sales in U.S..  Full Article

Veru reports Q3 loss per share $0.03
Tuesday, 8 Aug 2017 06:00am EDT 

Aug 8 (Reuters) - Veru Inc :Veru Inc reports fiscal third quarter financial results.Q3 loss per share $0.03.Qtrly unit sales totaled 8.5 million, which is 21 percent lower than 10.7 million from same prior-year quarter.Veru Inc qtrly net revenues $4.3 million versus $5.6 million.  Full Article